Opportunity Information: Apply for RFA HL 14 028
Apply for RFA HL 14 028
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Blood and Vascular Systems Response to Sepsis (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839 Blood Diseases and Resources Research 93.859 Biomedical Research and Research Training.
- This funding opportunity was created on Nov 1, 2013 and posted on Nov 1, 2013.
- Applicants must submit their applications by Feb 6, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: Special district governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Private institutions of higher education Small businesses State governments Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Independent school districts Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Blood and Vascular Systems Response to Sepsis (BVSS) Program R01 funding opportunity (RFA-HL-14-028) is a National Institutes of Health discretionary grant competition designed to push forward research on how sepsis disrupts the blood and vascular systems. The central scientific goal is to support multidisciplinary projects that can explain, at a cellular and molecular level, why severe endothelial dysfunction develops during sepsis and how that dysfunction contributes to two of the most dangerous clinical outcomes: sepsis-related coagulopathy (abnormal clotting and bleeding problems) and vascular collapse (loss of vascular tone and integrity leading to shock and organ failure). In practical terms, the FOA aims to bring together research partnerships that can combine expertise across fields to dissect the mechanisms that drive sepsis pathogenesis specifically through the lens of blood and vascular biology.
This opportunity uses the NIH R01 mechanism, meaning it is intended for hypothesis-driven, investigator-initiated style research projects, but within the targeted scope set by the BVSS initiative. Applications are expected to be more than single-discipline efforts; the FOA emphasizes integrated, cross-cutting approaches to untangle complex pathways and interactions. The work supported under this initiative would typically focus on mechanistic questions about endothelial cells and vascular function in sepsis, how inflammation intersects with coagulation, how vascular barrier disruption occurs, and what molecular or cellular events lead to progressive dysfunction severe enough to cause systemic coagulopathy and hemodynamic failure. The overarching intent is to generate foundational knowledge that clarifies why the vascular system fails in sepsis and to identify mechanistic nodes that could later be leveraged for therapeutic or diagnostic development, even if the FOA itself is framed around mechanistic discovery.
From an administrative standpoint, the FOA was posted on November 1, 2013, with an original and final application due date of February 6, 2014, and it was later archived on March 9, 2014. The award ceiling listed for this announcement is $500,000, and there is no cost-sharing or matching requirement. The activity categories are health-related and tied to CFDA listings 93.839 (Blood Diseases and Resources Research) and 93.859 (Biomedical Research and Research Training), reflecting the programmatic alignment with cardiovascular, hematologic, and broader biomedical research priorities. The funding instrument is a grant, consistent with NIH R01 support.
Eligibility for applicants is broad across U.S.-based organizations and government entities. Eligible applicants include public and private institutions of higher education, public and state-controlled universities, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (including small businesses and other than small businesses), and multiple levels of government such as state, county, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The FOA also explicitly includes a range of mission- and community-focused institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), and faith-based or community-based organizations, along with regional organizations and U.S. territories or possessions. At the same time, the announcement makes clear that foreign institutions are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by NIH policy) are not allowed under this FOA.
For applicants looking for the full official requirements, the NIH provided an additional information link to the complete announcement at http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-028.html. Technical issues accessing the announcement were directed to the NIH Office of Extramural Research webmaster contact listed in the notice. Overall, the BVSS R01 announcement is best understood as a targeted NIH effort to catalyze collaborative, mechanistic research that explains how sepsis drives endothelial injury and vascular failure, with the expectation that clearer mechanistic understanding will ultimately enable better strategies to predict, prevent, or treat sepsis-related coagulopathy and vascular collapse.
Frequently Asked Questions (FAQs): Blood and Vascular Systems Response to Sepsis (BVSS) Program (RFA-HL-14-028)
1. What is the BVSS Program R01 funding opportunity (RFA-HL-14-028)?
The Blood and Vascular Systems Response to Sepsis (BVSS) Program R01 funding opportunity (RFA-HL-14-028) is a National Institutes of Health (NIH) discretionary grant competition focused on advancing research into how sepsis disrupts the blood and vascular systems.
2. What is the main scientific goal of this FOA?
The central goal is to support multidisciplinary projects that explain, at cellular and molecular levels, why severe endothelial dysfunction develops during sepsis and how it contributes to two major clinical outcomes: sepsis-related coagulopathy and vascular collapse.
3. What specific sepsis outcomes does the FOA emphasize?
The FOA emphasizes two dangerous outcomes linked to vascular and blood system dysfunction in sepsis:
- Sepsis-related coagulopathy (abnormal clotting and bleeding problems)
- Vascular collapse (loss of vascular tone and integrity leading to shock and organ failure)
- How endothelial dysfunction contributes to both outcomes
4. What types of research approaches are expected?
Applications are expected to go beyond single-discipline efforts. The FOA emphasizes integrated, cross-cutting and multidisciplinary approaches to untangle complex pathways and interactions involved in sepsis pathogenesis, specifically through blood and vascular biology.
5. What topics or mechanistic areas are within scope?
Work supported under this initiative would typically focus on mechanistic questions such as:
- Endothelial cells and vascular function in sepsis
- How inflammation intersects with coagulation
- How vascular barrier disruption occurs
- Molecular or cellular events that lead to progressive dysfunction severe enough to cause systemic coagulopathy and hemodynamic failure
6. Is this opportunity focused on basic discovery or on developing therapies/diagnostics?
The FOA is framed around mechanistic discovery and generating foundational knowledge about why vascular failure occurs in sepsis. It also aims to identify mechanistic nodes that could later be leveraged for therapeutic or diagnostic development, even if direct product development is not the primary focus described.
7. What grant mechanism is used for this funding opportunity?
This opportunity uses the NIH R01 mechanism, intended for hypothesis-driven, investigator-initiated style research projects within the targeted scope of the BVSS initiative.
8. What is the award ceiling for this announcement?
The award ceiling listed for this FOA is $500,000.
9. Is cost-sharing or matching required?
No. The announcement states there is no cost-sharing or matching requirement.
10. When was the FOA posted and what were the application due dates?
Administrative dates provided for this FOA are:
- Posted date: November 1, 2013
- Original application due date: February 6, 2014
- Final application due date: February 6, 2014
- Archive date: March 9, 2014
11. What does it mean that the FOA is archived?
Based on the information provided, the FOA was archived on March 9, 2014, indicating it is no longer an active solicitation under that announcement.
12. What are the activity categories and CFDA listings associated with this opportunity?
The activity categories are health-related and tied to CFDA listings:
- 93.839 (Blood Diseases and Resources Research)
- 93.859 (Biomedical Research and Research Training)
13. What is the funding instrument?
The funding instrument is a grant, consistent with NIH R01 support.
14. Who is eligible to apply?
Eligibility is broad across U.S.-based organizations and government entities. Eligible applicants include:
- Public and private institutions of higher education
- Public and state-controlled institutions of higher education
- Nonprofit organizations (with or without 501(c)(3) status)
- For-profit organizations (including small businesses and other than small businesses)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public housing authorities/Indian housing authorities
- Regional organizations
- U.S. territories or possessions
15. Are mission- and community-focused institution types included as eligible applicants?
Yes. The FOA explicitly includes several institution types, including:
- Historically Black Colleges and Universities (HBCUs)
- Hispanic-serving institutions
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
- Faith-based or community-based organizations
16. Are foreign institutions eligible to apply?
No. The announcement states that foreign institutions are not eligible to apply.
17. Are non-U.S. components of U.S. organizations eligible?
No. The FOA states that non-U.S. components of U.S. organizations are not eligible.
18. Are foreign components (as defined by NIH policy) allowed under this FOA?
No. The FOA indicates that foreign components are not allowed under this opportunity.
19. What is the program trying to accomplish in practical terms?
In practical terms, the FOA is intended to catalyze research partnerships that combine expertise across fields to dissect mechanisms driving sepsis pathogenesis through the lens of blood and vascular biology, with an emphasis on endothelial injury and vascular failure.
20. Where can applicants find the official, complete announcement?
The NIH provided an additional information link to the complete announcement at:
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-028.html
21. Who should be contacted for technical issues accessing the announcement?
Technical issues accessing the announcement were directed to the NIH Office of Extramural Research webmaster contact listed in the notice.
22. What kind of collaboration does the FOA encourage?
The FOA encourages multidisciplinary and integrated research partnerships that bring together cross-field expertise to address complex interactions underlying endothelial dysfunction, coagulation abnormalities, vascular barrier disruption, and hemodynamic failure in sepsis.
23. How does this FOA define the overarching intent of the BVSS initiative?
The overarching intent is to generate foundational mechanistic knowledge that clarifies why the vascular system fails in sepsis, and to identify mechanistic nodes that could later inform improved strategies to predict, prevent, or treat sepsis-related coagulopathy and vascular collapse.
Browse more opportunities from the same category: Health
Next opportunity: STD/HIV Disease Intervention Services Training Centers (DISTC)
Previous opportunity: Primary Care Services Resources Coordination and Development
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 14 028
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 14 028) also looked into and applied for these:
| Funding Opportunity |
|---|
| STD/HIV Disease Intervention Services Training Centers (DISTC) Apply for CDC RFA PS14 1408 Funding Number: CDC RFA PS14 1408 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| HIV Early Intervention Services (EIS Program) Existing Geographic Service Areas (EISEGA) Apply for HRSA 14 059 Funding Number: HRSA 14 059 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Replication of Key Clinical Trials Initiative (U01) Apply for PAR 13 383 Funding Number: PAR 13 383 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening the Evidence Base and Capacity for Implementing HIV Prevention and Care and Treatment Programs in the Republic of South Africa under the United States Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1403 Funding Number: CDC RFA GH14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Technical Assistance to Support AIDS Directors and HIV Prevention Program Managers in the 50 States, District of Columbia, the Commonwealth of Puerto Rico, the US Virgin Islands, and the Pacific Islands Apply for CDC RFA PS14 1405 Funding Number: CDC RFA PS14 1405 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Limited Competition Collaborative Study on the Genetics of Alcoholism (COGA) (U10) Apply for RFA AA 14 001 Funding Number: RFA AA 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25) Apply for PAR 13 384 Funding Number: PAR 13 384 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| LINKAGES HIV SERVICES FOR KEY POPULATIONS Apply for SOL OAA 14 000013 Funding Number: SOL OAA 14 000013 Agency: Agency for International Development Category: Health Funding Amount: $72,000,000 |
| Systems Strengthening for Health Commodities Apply for RFA 617 14 000001 Funding Number: RFA 617 14 000001 Agency: Uganda USAID Kampala Category: Health Funding Amount: Case Dependent |
| Evaluation and Administration Coordinating Center for the Low Cost, Pragmatic, Patient Centered Randomized Controlled Intervention Trials (R01) Apply for RFA HL 14 020 Funding Number: RFA HL 14 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical, Epidemiologic and Ecologic Factors Impacting the Burden and Distribution of Monkeypox in Tshuapa District, Democratic Republic of the Congo Apply for RFA CK 14 002 Funding Number: RFA CK 14 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (Collaborative R01) Apply for PAR 13 391 Funding Number: PAR 13 391 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01) Apply for PAR 13 392 Funding Number: PAR 13 392 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory and Developmental Grant to Improve Health Care Quality through Health Information Technology (IT) (R21) Apply for PA 14 001 Funding Number: PA 14 001 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $200,000 |
| Epidemiology, Prevention, and Treatment of Influenza and Other Respiratory Infections in a Malaria Endemic Area of Malawi with High HIV Prevalence Apply for RFA IP 14 002 Funding Number: RFA IP 14 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,200,000 |
| Advancing Patient Safety Implementation through Safe Medication Use Research (R18) Apply for PA 14 002 Funding Number: PA 14 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Collaborative Activities to Promote Metabolomics Research (Admin Supp) Apply for PA 14 003 Funding Number: PA 14 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Rural Health Network Development Planning Program Apply for HRSA 14 043 Funding Number: HRSA 14 043 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| ATSDRs Program to Promote Localized Efforts To Reduce Environmental Exposure (APPLETREE) Apply for CDC RFA TS14 1403 Funding Number: CDC RFA TS14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| The Cooperative Re Engagement Controlled Trial (CoRECT) Apply for RFA PS 14 001 Funding Number: RFA PS 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 14 028", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.